文献速递白血病

menin抑制剂与激酶抑制剂联合治疗NUP98易位白血病有效

Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.
PubMed 文献 · Leukemia · 2024-06-18

研究探讨menin抑制剂MI-3454与CDK6抑制剂帕博西尼或FLT3抑制剂吉瑞替尼联合,在NUP98重排白血病模型中是否增强抗白血病效果。结果显示两种联合在患者样本中對细胞生长、集落形成和分化有强协同效应,并在患者来源异种移植模型中显著增强menin抑制剂的抗白血病疗效。

要点

  • menin抑制剂MI-3454联合帕博西尼或吉瑞替尼在NUP98重排白血病模型中显示强协同抗白血病效应。
  • 联合方案在患者来源异种移植模型中显著增强menin抑制剂的抗白血病疗效。
  • 两种联合影响与白血病发生相关的相似通路,包括细胞周期调控、增殖和分化。

核心结论

  • 研究为menin抑制剂与激酶抑制剂联合作为NUP98重排白血病新型治疗进入临床转化提供了有力依据,并支持表观遗传药物与激酶抑制剂尚未探索的联合。

研究设计与样本

  • 研究在NUP98重排白血病细胞模型、患者样本及患者来源异种移植模型中进行,评估menin抑制剂MI-3454与CDK6抑制剂帕博西尼或FLT3抑制剂吉瑞替尼联合的效应。

主要发现

  • menin抑制剂MI-3454与靶向CDK6的帕博西尼或靶向FLT3的吉瑞替尼联合,在NUP98重排白血病模型中强烈增强menin抑制的抗白血病效果。
  • 两种联合对NUP98易位患者样本的细胞生长、集落形成和分化均显示强协同效应。
  • 两种联合在NUP98重排白血病患者来源异种移植模型中显著增强menin抑制剂的抗白血病疗效。
  • 帕博西尼或吉瑞替尼与menin抑制剂联合时,尽管抑制两种不相关激酶,但影响与白血病发生相关的相似通路,包括细胞周期调控、细胞增殖和分化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chromosomal translocations of the nucleoporin 98 (NUP98) gene are found in acute myeloid leukemia (AML) patients leading to very poor outcomes. The oncogenic activity of NUP98 fusion proteins is dependent on the interaction between Mixed Lineage Leukemia 1 and menin. NUP98-rearranged (NUP98-r) leukemia cells also rely on specific kinases, including CDK6 and/or FLT3, suggesting that simultaneous targeting of these kinases and menin could overcome limited sensitivity to single agents. Here, we found that combinations of menin inhibitor, MI-3454, with kinase inhibitors targeting either CDK6 (Palbociclib) or FLT3 (Gilteritinib) strongly enhance the anti-leukemic effect of menin inhibition in NUP98-r leukemia models. We found strong synergistic effects of both combinations on cell growth, colony formation and differentiation in patient samples with NUP98 translocations. These combinations also markedly augmented anti-leukemic efficacy of menin inhibitor in Patient Derived Xenograft models of NUP98-r leukemia. Despite inhibiting two unrelated kinases, when Palbociclib or Gilteritinib were combined with the menin inhibitor, they affected similar pathways relevant to leukemogenesis, including cell cycle regulation, cell proliferation and differentiation. This study provides strong rationale for clinical translation of the combination of menin and kinase inhibitors as novel treatments for NUP98-r leukemia, supporting the unexplored combinations of epigenetic drugs with kinase inhibitors.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Miao H, Chen D, Ropa J, et al. Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations. Leukemia. 2024. PMID: 38890447. doi:10.1038/s41375-024-02312-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。